Dale Wolf - NuVasive VP Operations
| NUVADelisted Stock | USD 42.35 0.85 1.97% |
Insider
Dale Wolf is VP Operations of NuVasive
| Age | 43 |
| Phone | 858 909 1800 |
| Web | https://www.nuvasive.com |
Dale Wolf Latest Insider Activity
Tracking and analyzing the buying and selling activities of Dale Wolf against NuVasive stock is an integral part of due diligence when investing in NuVasive. Dale Wolf insider activity provides valuable insight into whether NuVasive is net buyers or sellers over its current business cycle. Note, NuVasive insiders must abide by specific rules, including filing SEC forms every time they buy or sell NuVasive'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Dale Wolf over a year ago Exercise or conversion by Dale Wolf of 4572 shares of NuVasive subject to Rule 16b-3 |
NuVasive Management Efficiency
The company has return on total asset (ROA) of 0.0242 % which means that it generated a profit of $0.0242 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0331 %, meaning that it created $0.0331 on every $100 dollars invested by stockholders. NuVasive's management efficiency ratios could be used to measure how well NuVasive manages its routine affairs as well as how well it operates its assets and liabilities.NuVasive currently holds 1.01 B in liabilities with Debt to Equity (D/E) ratio of 1.22, which is about average as compared to similar companies. NuVasive has a current ratio of 1.15, suggesting that it may not be capable to disburse its financial obligations when due. Note, when we think about NuVasive's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Lindsey Little | LivaNova PLC | N/A | |
| Urban Faeh | Bruker | N/A | |
| Stacey Desrochers | Bruker | N/A | |
| Lauren Cristina | Pulmonx Corp | N/A | |
| Alex Shvartsburg | LivaNova PLC | 54 | |
| Diana Scherer | Glaukos Corp | N/A | |
| Michelle Scharfenberg | Avanos Medical | N/A | |
| Tomas Navratil | Glaukos Corp | ||
| Joseph Powers | Si Bone | 64 | |
| Lee Rosenthal | Paragon 28 | N/A | |
| Julie Dewey | Nevro Corp | 63 | |
| Sri Radhakrishnan | Pulmonx Corp | N/A | |
| Steve Deitsch | Paragon 28 | N/A | |
| Barbara Schwarzentraub | CONMED | 53 | |
| Jason Edie | Paragon 28 | N/A | |
| David Haffner | Glaukos Corp | N/A | |
| Mark Quick | Orthofix Medical | N/A | |
| Michael Hutchinson | LivaNova PLC | 53 | |
| Sridhar Kosaraju | Nevro Corp | 42 | |
| Geoffrey Rose | Pulmonx Corp | 50 | |
| Laura MBA | Si Bone | 57 | |
Management Performance
| Return On Equity | 0.0331 | |||
| Return On Asset | 0.0242 |
NuVasive Leadership Team
Elected by the shareholders, the NuVasive's board of directors comprises two types of representatives: NuVasive inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NuVasive. The board's role is to monitor NuVasive's management team and ensure that shareholders' interests are well served. NuVasive's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NuVasive's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Juliet Cunningham, VP Relations | ||
| Sean Freeman, Sr Devel | ||
| Michael Farrington, VP Culture | ||
| Nathaniel Esq, Gen VP | ||
| Dale Wolf, VP Operations | ||
| Ryan Donahoe, VP Officer | ||
| Matthew Harbaugh, Ex CFO | ||
| Johnson Lai, Chief Officer | ||
| Marc Rosenbaum, Co VP | ||
| Christopher Barry, CEO, Director |
NuVasive Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NuVasive a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0331 | |||
| Return On Asset | 0.0242 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | 2.91 B | |||
| Shares Outstanding | 52.45 M | |||
| Shares Owned By Insiders | 0.27 % | |||
| Shares Owned By Institutions | 99.73 % | |||
| Number Of Shares Shorted | 5.76 M | |||
| Price To Earning | 51.79 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Other Consideration for investing in NuVasive Stock
If you are still planning to invest in NuVasive check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NuVasive's history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |